Press release: Lumera Labs Launches

KELOWNA, BC — May 4, 2026. Lumera Labs Inc., a Canadian research-chemical supplier, today announced the public launch of its HPLC-verified peptide reference standard catalog at lumerapeptide.com. The catalog includes 29 reference standards spanning metabolic, healing, growth-axis, longevity, neuro, and cosmetic research categories, with every lot independently tested by Janoshik Analytical.

"Canadian research labs deserve reference standards with the same chain-of-custody rigor as their U.S. and European peers," said the founder of Lumera Labs. "Three independent tests on every lot — HPLC purity, LC-MS identity, and LAL endotoxin clearance — and a public Certificate of Analysis the buyer can match to the batch number on the vial. That's what 'rigorously tested' means."

Each shipment leaves Kelowna in cold-chain insulated packaging maintained at −20°C, with a USB temperature logger included for orders ≥ $200 CAD. Domestic delivery is 24–48 hours via insulated courier, Canada-wide.

The launch catalog includes Semaglutide, Tirzepatide, Retatrutide, BPC-157, TB-500, CJC-1295, Ipamorelin, NAD+, GHK-Cu, MOTS-c, Thymosin Alpha-1, Epithalon, Pinealon, SS-31, PT-141, Kisspeptin-10, and 13 additional research compounds. All products are sold strictly for in-vitro laboratory research and are not approved by Health Canada or the FDA for human use.

About Lumera Labs

Lumera Labs Inc. is a Canadian supplier of research peptide reference standards based in Kelowna, British Columbia. The company supplies lyophilized peptide reference standards strictly for in-vitro laboratory research. Every lot is independently tested by Janoshik Analytical. Lumera Labs publishes a per-lot Certificate of Analysis for every product on its website.

Press contact

Editorial · partnerships · review samples: lumeralabs@proton.me

Press kit: lumerapeptide.com/press/

###